EN DE
Watch Epsilon Healthcare Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Epsilon Healthcare Ltd (EPN) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Epsilon Healthcare Ltd stock A$0.02, price A$0.02, that is 4.6% below the price, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000137598

EH Epsilon Healthcare Ltd logo Thin data Nov 10, 2026

Epsilon Healthcare Ltd

EPN · AU

Rising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Revenue last quarter +123% vs. a year ago. 
Fair value A$0.0229 · Fairly valued 
Mixed Growth (revenue 5y +5.0 %/yr in AUD) 
Thin margins · 0.5% net margin (TTM) 
Mixed vs. peers (4/9) 
Quality 38/100 
Negative free cash flow 
Narrow moat 33/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Epsilon Healthcare Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.1650 A$0.0160 Fair Value A$0.0229 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0160 – A$0.1650 · fair‑value band A$0.0216 – A$0.0242 · the A$0.0240 price screens above the A$0.0229 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Epsilon Healthcare in your weekly email

Every Wednesday you see whether Epsilon Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Epsilon Healthcare Limited, together with its subsidiaries, engages in the healthcare business in Australia. The company operates in three segments, Contract Development and Manufacturing Activities, Telehealth Medical Practice Services, and Pharmacy Services.

Show moreShow less

It is involved in the healthcare and clinics operation; pharmaceutical contract development and manufacturing; development and manufacturing of active pharmaceutical ingredients and finished formulation; and provision of pharmacy services and patient care.

The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Southport, Australia.

Stock analysis

Epsilon Healthcare Ltd (EPN) currently trades at A$0.0240, while our estimate is A$0.0229, so the stock looks roughly fairly valued today (gap 4.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0216 (bear) to A$0.0242 (bull), the price of A$0.0240 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Epsilon Healthcare Ltd reported revenue of A$9.4M in FY2025 versus A$5.5M in FY2021, a compound +14.3%/yr. Reported net income was −A$2.1M in FY2025.

Key figures

Market cap A$9.3M (≈ $6.4M) Micro · P/S ratio 0.60 · Net margin 0.5% · Return on equity 50.3% · Return on assets (EBIT) −22.0% (5-year average) · Operating margin −15.8% · Revenue (TTM) A$13.6M · Revenue growth (YoY) +123%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −5%, EPN screens cheaper than that median.

Fair Value

Bear A$0.0216 Fair Value A$0.0229 Bull A$0.0242
Price A$0.0240 · Downside -4.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 76
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 55
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 30
Distance to the 52-week high, does not count
New shares 28
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+67.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−140.6% (2020) → −23.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch EPN, get fair value alerts →

Compare Epsilon Healthcare Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −4.6% · Above median
Profitability
Return on equity (12 months) 50.3% · Top 25%
Return on assets −11.5% · Bottom 25%
Net margin (12 months) 0.5% · Below median
Operating margin (12 months) −15.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 123.0% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 3.12× · Pricier than median
P/S (12 months) 0.69× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)100 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.96 $113.53 +37% vs EPN
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.93 ¥53.04 +11% vs EPN
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,885 ₹1,983 +5% vs EPN
Haleon plc HLN $9.09 $8.62 −5% vs EPN
Merck KGaA MRK €148.15 €108.83 −27% vs EPN
Galderma Group GALD CHF 194.40 CHF 111.92 −42% vs EPN
Takeda Pharmaceutical Company TAK $21.12 $11.34 −46% vs EPN
Teva Pharmaceutical Industries Limited TEVA $43.65 $20.74 −52% vs EPN
Sandoz Group SDZ CHF 86.90 CHF 40.54 −53% vs EPN
Divi's Laboratories Limited DIVISLAB ₹11,485 ₹1,567 −86% vs EPN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Epsilon Healthcare Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Epsilon Healthcare Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EPN

Frequently asked questions

Is Epsilon Healthcare Ltd (EPN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0229 versus a price of A$0.0240, about 5% lower (fairly valued).
What is the fair value of EPN?
Our estimate for Epsilon Healthcare Ltd is A$0.0229 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0240.
What is the quality score of EPN?
Epsilon Healthcare Ltd has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Epsilon Healthcare Ltd (EPN)?
Our calculated price target is the estimate of A$0.0229 (as of Nov 10, 2026). Cautious scenario A$0.0216, optimistic scenario A$0.0242. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Epsilon Healthcare Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0229, about 5% lower versus a price of A$0.0240 (fairly valued). Cautious scenario A$0.0216, optimistic scenario A$0.0242. The calculation is refreshed regularly with new filings.
What is the revenue of Epsilon Healthcare Ltd (EPN)?
Epsilon Healthcare Ltd reported trailing-twelve-month revenue of about A$13.6M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Epsilon Healthcare Ltd (EPN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Epsilon Healthcare Ltd it is A$0.0229 per share (as of Nov 10, 2026), against a price of A$0.0240.
Is Epsilon Healthcare Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, EPN trades above its calculated fair value: price A$0.0240, fair value A$0.0229, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EPN?
No. The price is what the market pays today (A$0.0240); the fair value is what the company's own numbers justify (A$0.0229). For Epsilon Healthcare Ltd the two are A$0.0011 per share apart. That gap is exactly why we show both numbers side by side.
How much is Epsilon Healthcare Ltd worth?
The market values Epsilon Healthcare Ltd at about A$9.3M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0240; our models calculate a fair value of A$0.0229 per share.
What do the bullish and bearish scenarios say about EPN?
Our models span a range for Epsilon Healthcare Ltd: cautious scenario A$0.0216, base A$0.0229, optimistic A$0.0242 per share (as of Nov 10, 2026, price A$0.0240). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Epsilon Healthcare Ltd (EPN)?
Balance-sheet figures for Epsilon Healthcare Ltd (as of Nov 10, 2026): return on equity 50.3%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is EPN from its 52-week high?
Epsilon Healthcare Ltd trades at A$0.0240, about 37% below its 52-week high of A$0.0380 and 26% above the low of A$0.0190 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0229 is for.
Which stocks are comparable to Epsilon Healthcare Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Epsilon Healthcare Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0240, calculated fair value A$0.0229 (−5%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Epsilon Healthcare Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Epsilon Healthcare Ltd (EPN)?
The closing price on Nov 11, 2026 was A$0.0240. Our estimate is A$0.0229, about 5% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Epsilon Healthcare Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (A$0.0216 to A$0.0242), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Epsilon Healthcare Ltd

How large is the market capitalisation of Epsilon Healthcare Ltd (EPN)?
The market capitalisation of Epsilon Healthcare Ltd is A$9.3M (≈ $6.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Epsilon Healthcare Ltd (EPN)?
The price-to-sales ratio of Epsilon Healthcare Ltd is 0.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Epsilon Healthcare Ltd (EPN)?
The net margin of Epsilon Healthcare Ltd is 0.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Epsilon Healthcare Ltd (EPN)?
The return on equity (ROE) of Epsilon Healthcare Ltd is 50.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Epsilon Healthcare Ltd (EPN)?
On an EBIT basis the return on assets of Epsilon Healthcare Ltd is −22.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Epsilon Healthcare Ltd (EPN)?
The operating margin of Epsilon Healthcare Ltd is −15.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Epsilon Healthcare Ltd (EPN)?
Revenue at Epsilon Healthcare Ltd is growing +123% versus a year earlier (3y avg +9.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Epsilon Healthcare Ltd (EPN) generate?
The free cash flow of Epsilon Healthcare Ltd is −A$3.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Epsilon Healthcare Ltd (EPN) carry?
The net debt of Epsilon Healthcare Ltd is A$13.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Epsilon Healthcare Ltd in the live analysis

One click puts Epsilon Healthcare Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.